Avasimibe (Synonyms: CI-1011; PD-148515)

Name: Avasimibe
Brand: MedChemExpress
SKU: HY-13215
Rating: 5.0 (11 reviews)

Cat. No.: HY-13215 Purity: 99.77%: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC₅₀s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer.

For research use only. We do not sell to patients.

Avasimibe Chemical Structure

CAS No. : 166518-60-1

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

9 Publications Citing Use of MCE Avasimibe

Cell Viability Assay

RT-PCR

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; qRT-PCR data showing the expression of linc00339 in T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

: Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508. [Abstract]; The effect of Avasimibe on the viability of T98 G is dose-dependent and time-dependent. Similar results are found in LN229 as well. Avasimibe has an anti-tumour effect on glioma.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Acyltransferase Isoform Specific Products:

View All Isoforms

ACAT1 ACAT2 MGAT2 ACAT

Biological Activity
Purity & Documentation
References
Customer Review

Description

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC₅₀s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively^[1]. Avasimibe can be used for the research of prostate cancer^[2].

IC₅₀ & Target^[1]

ACAT1

24 μM (IC₅₀)

ACAT2

9.2 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	13.71 μM Compound: AVASIMIBE	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	3.93 μM Compound: AVASIMIBE	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1

In Vitro

Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 μM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells^[2].
Avasimibe (10 and 20 μM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT)^[2].
Avasimibe (10 and 20 μM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells^[2].
Avasimibe (10 and 20 μM) inhibits the metastasis of PCa cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	0, 0.25, 5, 10, 20, 40 and 80 µM
Incubation Time:	1, 2, and 3 days
Result:	Dose dependently inhibited PC-3 and DU 145 cell viability.

Western Blot Analysis^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	10 and 20 µM
Incubation Time:	48 hours
Result:	Reduced protein levels of EMT-related proteins (β-catenin, Vimentin, N-cadherin, Snail, MMP9 and E-cadherin).

Cell Cycle Analysis^[2]

Cell Line:	PCa cells (PC-3 and DU 145)
Concentration:	10 and 20 µM
Incubation Time:	48 hours
Result:	Induced G1 phase cycle arrest and altered the G1 phase-related protein levels in PCa cells.

In Vivo

Avasimibe (30 mg/kg, intraperitoneally injected on alternate days for 7 weeks) suppresses PCa cell growth and metastasis in vivo. Avasimibe has good biocompatibility and low toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SPF male mice (BALB/c-nude, 4 weeks old) bearing PCa cells^[2]
Dosage:	30 mg/kg
Administration:	Intraperitoneally injected for 7 weeks
Result:	Reduced tumour volume compared with that of the control group. Inhibited PCa growth and migration in vivo.

Molecular Weight

501.72

Formula

C₂₉H₄₃NO₄S

CAS No.

166518-60-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(NS(=O)(OC1=C(C(C)C)C=CC=C1C(C)C)=O)CC2=C(C(C)C)C=C(C(C)C)C=C2C(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (199.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9931 mL	9.9657 mL	19.9314 mL
5 mM	0.3986 mL	1.9931 mL	3.9863 mL
10 mM	0.1993 mL	0.9966 mL	1.9931 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 7.5 mg/mL (14.95 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 7.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (249 KB) LCMS (89 KB)

Handling Instructions (2659 KB)

References

[1]. Taichi Ohshiro,et al. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1108-15. [Content Brief]

[2]. Kangping Xiong, et al. The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer.Cancer Cell Int. 2021 Aug 30;21(1):461. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9931 mL	9.9657 mL	19.9314 mL	49.8286 mL
	5 mM	0.3986 mL	1.9931 mL	3.9863 mL	9.9657 mL
	10 mM	0.1993 mL	0.9966 mL	1.9931 mL	4.9829 mL
	15 mM	0.1329 mL	0.6644 mL	1.3288 mL	3.3219 mL
	20 mM	0.0997 mL	0.4983 mL	0.9966 mL	2.4914 mL
	25 mM	0.0797 mL	0.3986 mL	0.7973 mL	1.9931 mL
	30 mM	0.0664 mL	0.3322 mL	0.6644 mL	1.6610 mL
	40 mM	0.0498 mL	0.2491 mL	0.4983 mL	1.2457 mL
	50 mM	0.0399 mL	0.1993 mL	0.3986 mL	0.9966 mL
	60 mM	0.0332 mL	0.1661 mL	0.3322 mL	0.8305 mL
	80 mM	0.0249 mL	0.1246 mL	0.2491 mL	0.6229 mL
	100 mM	0.0199 mL	0.0997 mL	0.1993 mL	0.4983 mL

Avasimibe Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Avasimibe (Synonyms: CI-1011; PD-148515)

Customer Review

Avasimibe Related Antibodies

9 Publications Citing Use of MCE Avasimibe

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Acyltransferase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Avasimibe Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Avasimibe Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report